INTRODUCTION
The HER-2/neu oncogene is overexpressed in 25-30% of breast cancers (1) . Amplification and/or overexpression of HER-2 is associated with a worse clinical outcome in patients with newly diagnosed primary breast cancer (2) .
The human epidermal growth factor receptor 2 (HER-2)/ neu (c-erbB-2) gene is localized to chromosome 17q and encodes a transmembrane tyrosine kinase receptor protein (3) . This Mr 185,000 transmembrane protein (p185) is a member of the epithelial HER family, which also includes the epidermal growth factor receptor (HER-1/c-erbB1), HER-3, and HER-4(4). The complete protein consists of three portions: an internal cytoplasmic structure with tyrosine kinase activity, a short hydrophobic transmembrane section, and an extracellular ligand-binding domain (5) . The extracellular domain (ECD) of the receptor protein can be cleaved from the cell surface by matrix metalloproteases and then released into blood (6) where it can be detected by ELISA in upto 45% of advanced breast cancer (7) .Patients with elevated serum Her-2/neu levels had significantly shorter medium survival times than those with normal serum HER-2/neu levels (8) .
Clinical studies have demonstrated that alterations in HER-2/ neu predict poor prognosis for breast cancer and are associated with features of tumor aggressiveness, such as absence of estrogen and progesterone receptors, high rate of cellular proliferation, advanced tumor stage, large tumor size, and young age at diagnosis (9) . Women with HER-2/ neu positive breast cancer have a worse prognosis than those with HER-2/neu negative cancers (10) . Different strategies to target HER-2/neu protein in HER-2/neu overexpressing cancer cells have been developed which inhibit either HER-2/neu protein function or expression (11) . The humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin ® ) is a new treatment modality for metastatic breast cancer, the efficacy of which is directly correlated with the HER-2 status of the tumour, evaluated either by immunohistochemistry (IHC) and/or by fluorescence in situ hybridisation (12) . Another method under investigation for predicting response to trastuzumab is the quantification of serum levels of the HER-2 ECD (13). The choice of the method used to identify patients who may benefit from this therapy is crucial (14) . The various methods for determining HER-2/neu gene and/or protein abnormalities in breast cancer specimens are compared in Table 1 (13, 15, 16) .
Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify overexpression or amplification of the HER-2(HER2, symbol ERBB2) gene, but each technique requires a high-quality tissue sample, which may not be available (17) . Besides the small percentage of biopsies that are performed are infrequently investigated for Her-2 overexpression, and repeated biopsies cannot be performed to evaluate the additional changes that are likely to accompany cancer progression. In contrast, obtaining a blood sample is safe and can be performed repeatedly (18) The objective of our study is to compare the assay HER-2/ neu by immunohistochemistry and the enzyme linked immmunosorbent assay (ELISA) techniques.
MATERIALS AND METHODS
Formalin-fixed, paraffin-embedded invasive breast tumors from 100 patients treated at the Kidwai Memorial Institute of Oncology between 2004 and 2005 were used for this correlative study. Carcinomas included 96% invasive ductal and 4% invasive lobular types. Histologically confirmed invasive carcinoma of the breast in different stages of the disease (100 patients), in the age group of 25-70 years were included. Age matched (±2 years) healthy female controls (100 cases) were selected from patient relatives. Serum samples were collected from patients before surgery. The study protocol was approved by the Ethics committee of Kidwai Memorial Institute of Oncology, Bangalore. A written informed consent was obtained from each patient.
Immunohistochemistry: Overexpression of HER-2/neu protein was detected by IHC using Rabbit Monoclonal antibody, (Labvision, UK) which targets the extracellular domain of p185 HER-2/neu . Four micron sections were cut from formalin fixed paraffin embedded tissue blocks, float mounted on adhesive coated glass slides, deparaffinized in xylene (Ranbaxy) and ethanol (Ranbaxy). Sections were quenched with fresh 3%hydrogen peroxide block (Labvision, UK) to inhibit endogenous tissue peroxidase activity for 5 minutes and rinsed with deionised water. Sections were then boiled in 100 ml antigen retrieval citrate (Sigma) buffer (0.01M), pH 6.0 for 40 minutes. The slides were allowed to cool for 20 minutes and subsequently rinsed thoroughly in deionised water and then with Tris (Sigma) buffer. Sections were incubated in unlabelled blocking serum solution for five to ten minutes and then incubated for 1 hour with primary antibody (Labvision, UK) at a dilution of 1:100 in buffer. Subsequently, sections were washed in Tris buffer, and then incubated first with biotinylated secondary antibody (Labvision,UK) solution for 30 minutes, washed with Tris buffer and again incubated with horseradish peroxidase conjugated streptavidin-biotin complex(Labvision, UK) for 30 minutes. Subsequently colour was developed using diaminobenzidine (Labvision,UK). Sections were then counterstained with haematoxylin (Nice chemicals) and were then mounted using mountant (Nice chemicals).Only formalinfixed materials were used for the study.
Immunostained slides were examined by light microscopy. For each batch of experiment, formalin fixed paraffin-embedded cell block (which was previously shown to overexpress HER-2/neu) was taken as positive control ( Figure 1A ) and a negative control (without adding primary antibody) was included. A sample was judged to be positive when distinct membrane staining of tumor cells was observed and visually compared with no staining on the surrounding normal epithelia and no staining in the negative control cells. Each specimen was scored semiquantitatively as to the intensity of membrane immunostaining on a four point scale, with 0 indicating absence of staininig , 1+ indicating non homogenous weak staining(<10% of membrane staining). To qualify for 2+ and 3+ scoring, complete membrane staining of more than 10% of tumor cells had to be observed. Scores of 0 or 1+ were considered negative for HER-2 overexpression; scores of 2+ were considered weakly positive; and scores of 3+ were considered strongly positive (19) .
ELISA : Sera from patients and controls were drawn by venipuncture in the fasting state. The blood was allowed to clot and the serum separated and stored in labeled containers at -20ºC till the day of the assay. The levels of serum HER-2/ neu were measured by sandwich enzyme immunoassay (20) . An anti-sp185 HER-2 human monoclonal coating antibody was adsorbed on to micro wells (Bender Med System USA). sp185 HER-2 present in the sample or standards bound to antibodies adsorbed to the micro wells; a horse radish peroxidase (HRP) conjugated monoclonal anti-sp185 HER-2 antibody was added and bound to sp185 HER-2 captured by the first antibody. Following incubation, unbound enzyme conjugated anti-sp185 HER-2 was removed by washing and substrate tetramethylbenzidine (TMB) solution reactive with HRP was added to the wells. TMB substrate reacts with HRP and produced the colour. The coloured product formed was in proportion to the amount of soluble p185HER-2 present in the sample. The reaction was terminated by addition of sulphuric acid and absorbance was measured at 450 nm (TECAN ELISA READER). A standard curve was prepared from 10 ng/ml stock standard sp185HER-2 by serially diluting as 5, 2.5, 1.25, 0.625, 0.312 and 0.156 ng/ml with assay buffer and sample concentration determined (Table 2) . Cut off value used in this study was 15ng/ml as per kit recommendation. The observed range in control individual for HER-2/neu was 3.5-13.5 ng/ml which was found to match the cut off range as per kit recommendation. Inter-batch imprecision : Precision check for HER-2/neu has been done and the values are given in Table-3 .
Comparison of Bender med system & Nichirei ELISA :
The proposed method has been compared with the following method (beaded assay) with a coefficient of variation of 1.8%for intra assay and 2.4% for inter assay. The cut off value 2 (0.95 ng/μl) for 2 h at room temperature. The bead was washed in saline again and incubated with 300 μl of a mixture of ophenylenediamine dihydrochloride (OPD) (2 mg/ml) and sodium perborate for 30 min at room temperature. After the reaction had been stopped by adding 2 ml of phosphoric acid, the absorbance of the reaction mixture was measured at 492 nm. The level of HER-2/neu protein was calculated from a calibration graph constructed with the use of recombinant HER-2/neu (Nichirei). Table 4 shows the comparison of Bender med system & Nichirei ELISA values.
Statistical analysis:
Pearson correlation (r value) test was used to calculate correlation between serum HER-2/neu levels and tissue HER-2/neu levels. Student't' test was used to find the significance. P value<0.001 was considered to be significant.
RESULTS
Tissues and serum from 100 patients were assayed by IHC and ELISA and the values are given in Table 5 . The age of patients selected for this study ranged from 25 to 70 years.53 patients were premenopausal, 38 patients were postmenopausal and the menopausal status of 9 patients was not known. Clinically healthy individuals were used as controls.
IHC: Immunohistochemical analysis using rabbit monoclonal antibody detected 29cases with HER-2/neu overexpression (16 as 2+, and 13 as 3+) and 71 cases were negative for HER-2/neu overexpression ( Figure 1B & 1C) . ELISA method using anti-sp185 HER-2 human monoclonal antibody detected 42 cases with HER-2/neu overexpression. Baseline concentrations of serum HER-2/neu were elevated (that is, = 15 ng/ml) in 42% (42) of the 100 evaluable patients and 58% cases were HER-2 negative (HER-2/neu <15ng/ml). The Mean and SEM of serum Her-2/neu positive group was 45.58+3.45ng/ml and for HER-2/neu negative group was 10.30+0.28ng/ml. A statistically significant correlation (P<0.001, r = 0.53,) was observed between serum HER-2/ neu and tissue HER-2/neu. Serum HER-2 was > 15ng/ml in 42% of the patients, including 22 from the tissue HER-2/neu positive group (n=100) and 20 from the tissue HER-2/neu negative group (n=100). Serum HER-2 was < 15ng/ml in 58 % of the patients, including 51 from the tissue HER-2/neu negative group (n=100) and 7 from the tissue HER-2/neu positive group (n=100).
DISCUSSION
The need for accurate detection of the HER-2 alteration has now become even more important, because therapeutic decisions for patients are increasingly dependent on this information. Moreover, it is currently the sole criteria for the selection of patients for HER-2/neu targeted therapy with the recombinant humanized anti-p185 HER-2/neu antibody trastuzumab (Herceptin) (23) .Trastuzumab is one of the few drugs whose indication depends on the results of a diagnostic test, and accurate and precise determination of HER-2 status is therefore essential. At present it is recommended that more than one method be used for this purpose (6) . The "best" method to measure HER-2 has become a point of controversy Table 6 .
False negatives arise by IHC when the test is performed improperly or when antigen is lost during fixation or processing of tissues (24) . There may be several reasons for this phenomenon. Many laboratories perform the staining on referred specimens and cannot control the time and nature of tissue fixation, the method of tissue processing, or the temperature of the paraffin embedding procedure, all of which can influence HER-2/neu protein antigen loss. Prolonged storage can also be a problem, and significant loss of tumormarker immunostaining intensity has been identified, particularly when specimens are stored as unstained slides. The impact of the fixative has been considered and shown to have a significant impact on HER-2/neu immunostaining (25) . False-positive results are a significant problem when IHC is exclusively used to test for HER-2/neu overexpression (26) . False positives arise from binding of the antibody in question to nonspecific proteins (24) .In the case of false positivity by ELISA Sun-Young Kong et al reported that some cases with negative tissue HER-2 expression showed high serum HER-2 ECD concentrations (up to 500.4μg/L), which might be attributable to transformation of tissue HER-2 status at disease recurrence, as has been reported (17) .
Advantages of IHC testing include its wide availability, relatively low cost, easy preservation of stained slides, and use of a familiar routine microscope (3). However, variable fixation protocols and subjective grading can cause difficulty in interpretation (27) . ELISA's have been used since 1991 to quantify either the full-length p185 in tumor tissue or the soluble circulating HER-2/neu ECD in serum or plasma (28) . The ELISA technique when performed on tumor cytosols made from fresh tissue samples avoids the potential antigen damage associated with fixation, embedding, and uncontrolled storage (25) . The readout for ELISA is relatively rapid compared to IHC. In addition, ELISA eliminates the need for biopsy. Furthermore, because there is a correlation between ECD/ HER-2 levels and HER-2 expression in the tumor, the selection of patients for trastuzumab therapy on the basis of high ECD/ HER-2 levels may be considered if tissue is not available (29) .
In this study we revealed a statistically significant (P <0.001) association between tissue HER-2/neu and serum HER-2 ECD levels. Immunohistochemistry for the detection of HER-2/neu protein overexpression showed a very good correlation (r = 0.53) with the results of ELISA. In conclusion our study showed that for routine diagnostics, the combination of IHC and ELISA is useful. Furthermore, ELISA can be used if the primary tissue sample is not available for predicting tissue HER-2 status.
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